Vir Biotechnology Appoints Brent Sabatini as Interim CFO Following Jason O'Byrne's Resignation

Details on O'Byrne’s Resignation and Transition Timeline

Jason O'Byrne notified Vir Biotechnology on July 20, 2026, of his decision to resign as Executive Vice President and Chief Financial Officer, effective August 3, 2026, to pursue other opportunities. The company’s filing clarifies that his resignation is not due to any disagreements regarding company operations, policies, or practices, a key detail for investors assessing executive turnover.

Following this announcement, Vir Biotechnology has commenced a search for a permanent CFO. Meanwhile, the company has appointed an internal candidate to serve as interim principal financial officer, ensuring a seamless transition with a two-week notice period ahead of the August 3 effective date.

Brent Sabatini Named Interim Principal Financial Officer

On July 23, 2026, Vir Biotechnology’s Board appointed Brent Sabatini, CPA, MBA, as interim principal financial officer effective August 3, 2026. Sabatini, 52, has been Senior Vice President and Chief Accounting Officer since February 2023 and principal accounting officer since October 2024. His promotion reflects a move from within the company’s finance leadership.

The filing confirms no arrangements or understandings influenced Sabatini’s selection, and no familial relationships exist between him and any Vir Biotechnology directors or executives. Additionally, Sabatini has no interests in transactions requiring disclosure under Item 404(a) of Regulation S-K, underscoring the independence of his appointment.

Sabatini’s Extensive Finance and Accounting Expertise

Brent Sabatini brings more than 20 years of finance and accounting leadership experience to his interim CFO role. Prior to joining Vir Biotechnology, he served as Head of Finance at Capsida Biotherapeutics from March 2021 to February 2023, gaining valuable biotherapeutics sector experience. Before that, Sabatini spent nearly 17 years at Amgen Inc. (April 2004 to March 2021), advancing through roles in Accounting, Tax, and Financial Planning and Analysis.

Sabatini holds a CPA license and earned a Bachelor of Science in Accountancy from California State University, Northridge, as well as an MBA from the University of Michigan’s Stephen M. Ross School of Business. These credentials, combined with his leadership background, equip him with the technical and strategic expertise expected of a chief financial officer.

Compensation and Interim Role Terms

The filing specifies that Sabatini will not receive any additional or adjusted compensation for serving as interim principal financial officer. This indicates the company views the interim CFO duties as an extension of his current Senior Vice President and Chief Accounting Officer responsibilities, suggesting the interim period is expected to be brief while a permanent CFO is sought.

This no-extra-pay approach highlights Vir Biotechnology’s focus on cost efficiency during the leadership transition and may reassure investors monitoring executive compensation practices.

Governance Disclosures and Independence Confirmations

Vir Biotechnology’s announcement includes standard governance disclosures confirming no undisclosed agreements influenced Sabatini’s appointment. It also affirms the absence of family ties between Sabatini and any company directors or executives, mitigating nepotism concerns.

The filing further states Sabatini has no interests in related-party transactions under Regulation S-K Item 404(a), reinforcing the propriety and independence of his interim CFO appointment.

Continuity in Financial Leadership and Accounting Oversight

Before his interim CFO appointment, Sabatini served as principal accounting officer since October 2024, a role involving key responsibilities under the Sarbanes-Oxley Act. His familiarity with Vir Biotechnology’s accounting policies, internal controls, and financial reporting processes is expected to facilitate a smooth transition.

His broad experience across accounting, tax planning, and financial analysis from prior roles at Amgen and Capsida positions him well to oversee both accounting operations and wider financial management functions during the interim period.

Ongoing Search for Permanent CFO

Vir Biotechnology has initiated a search for a permanent CFO successor to Jason O'Byrne but has not disclosed details about the process or timeline. Investors will likely monitor future updates regarding the permanent appointment and the duration of the interim period.

Appointing Sabatini internally ensures experienced leadership continuity while the company evaluates candidates, reflecting a strategic approach to executive succession.

Regulatory and Market Context

Vir Biotechnology, headquartered in San Francisco, California, is a Delaware corporation trading on the Nasdaq Global Select Market under the ticker VIR. The company’s Commission File Number is 001-39083, and its IRS Employer Identification Number is 81-2730369. As a publicly listed entity, Vir Biotechnology complies with federal securities laws requiring timely disclosure of significant executive leadership changes, which it fulfilled via a Form 8-K filing.

Executive transitions in biotechnology firms are closely watched by investors due to the critical role of financial leadership in capital management, regulatory compliance, and strategic planning. The prompt internal appointment of an interim CFO may signal strong continuity planning to the market.

Impact on Financial Reporting and Certifications

With Sabatini’s appointment effective August 3, 2026, he assumes responsibilities related to financial statement certifications and internal control assessments under the Sarbanes-Oxley Act Sections 302 and 906. This change in certifying officer is disclosed as part of the company’s regulatory obligations.

The timing of Sabatini’s interim CFO role ensures continuous coverage of these critical financial reporting functions, preventing gaps during the leadership transition.